Found 4 articles for: "Food and Drug Administration"
Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
May 2026 | Volume 25 | Issue 5 | Original Article | 413 | Copyright © May 2026
Background: Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are ...
Read MoreEfficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study
May 2026 | Volume 25 | Issue 5 | Original Article | 435 | Copyright © May 2026
Background: Melasma is an acquired pigmentary disorder characterized by symmetrical hyperpigmented macules and patches on sun-exposed areas, primarily the face. Kligman's formula...
Read MoreHydroquinone and Emerging Depigmenting Agents: Clinical Guidelines, Regulatory History, and Global Safety Considerations
April 2026 | Volume 25 | Issue 4 | Original Article | 363 | Copyright © April 2026
Hydroquinone has long served as the gold standard for hyperpigmentation treatment, but safety concerns, regulatory changes, and growing interest in non-hydroquinone therapies have prompted reeval...
Read MoreRapid Clearance of Lichen Planus With Topical Tapinarof
April 2026 | Volume 25 | Issue 4 | Case Reports | 381 | Copyright © April 2026
Background: Lichen planus (LP) is an auto-inflammatory idiopathic condition affecting skin, mucous membranes, hair follicles, and nails that presents as pruritic, violaceous papu...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
